Reaching 90-90-90 in Botswana.


Journal

Current opinion in HIV and AIDS
ISSN: 1746-6318
Titre abrégé: Curr Opin HIV AIDS
Pays: United States
ID NLM: 101264945

Informations de publication

Date de publication:
11 2019
Historique:
pubmed: 27 8 2019
medline: 1 8 2020
entrez: 27 8 2019
Statut: ppublish

Résumé

Botswana, a small country in southern Africa, has had a very high prevalence of HIV since about 1995. It seems important to analyze the response of this country to help us understand how it became one of the first nations to achieve the 90-90-90 targets. Botswana began a national program for treatment of HIV/AIDS with ARVs in 2002. Initially established in the four largest population centers, it expanded to more than 30 sites throughout the country by 2004. Also in 2004, an 'opt out' system for HIV testing was introduced. The government-sponsored ARV regimen for initiation was ZDV/3TC/EFV until 2008, then TDF/FTC/EFV until 2016, when it became TDF/FTC/DTG along with the introduction of treatment for all. Levels of both acquired and transmitted drug resistance have been low. In late 2013, we began the Ya Tsie or Botswana Combination Prevention Project (BCCP), a cluster randomized trial for 100 000 exurban and rural adults in 30 villages that included enhanced testing, linkage to care, and ARV treatment for 15 intervention villages, one in each pair. A 20% baseline survey in 2013-2015 revealed 29% prevalence and values that were already close to 90-90-90. With 83.3% of HIV-positive adults knowing they were infected, 87.4% of those knowing they were infected already on ARV, and 96.5% of those on ARV in complete viral suppression, this represented a combined value of 70.2% toward the target of 73%. By best estimates, incidence fell by about 30% over the 29-month period of the trial, which is compatible with Botswana reaching a 90% reduction in incidence in 10 years as proposed by the UNAIDS model. On the basis of an end-of-study survey in three intervention villages, we estimate that Botswana could reach 95-95-95 by 2019. These results illustrate that it is possible to reach 90-90-90 in countries with very high HIV prevalence.

Identifiants

pubmed: 31449090
doi: 10.1097/COH.0000000000000580
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

442-448

Auteurs

M Essex (M)

Harvard T.H. Chan School of Public Health AIDS Initiative, Boston, Massachusetts, USA.
Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.

Joseph Makhema (J)

Harvard T.H. Chan School of Public Health AIDS Initiative, Boston, Massachusetts, USA.
Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.

Shahin Lockman (S)

Harvard T.H. Chan School of Public Health AIDS Initiative, Boston, Massachusetts, USA.
Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Brigham and Women's Hospital, Boston, Massachusetts, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH